Welcome to our dedicated page for Polyrizon news (Ticker: PLRZ), a resource for investors and traders seeking the latest updates and insights on Polyrizon stock.
Polyrizon Ltd. (Nasdaq: PLRZ) generates news as a development-stage biotechnology company focused on intranasal hydrogels and barrier-forming nasal sprays. Company announcements highlight progress across its Capture and Contain™ (C&C) and Trap & Target™ (T&T) platforms, including updates on allergy, viral exposure reduction, and intranasal drug delivery programs.
Readers following Polyrizon news can expect coverage of preclinical study results, regulatory interactions, and product branding milestones. Recent press releases describe positive in-vitro data for PL-14 Allergy Blocker, including allergen-blocking performance compared with a standard comparator, and the completion of a branding process that will see PL-14 marketed as NASARIX™. Other updates focus on PL-16 Viral Blocker, a non-pharmacological intranasal hydrogel spray designed to form a temporary physical barrier on the nasal mucosa, with reported preclinical evidence of protection against certain respiratory viruses.
Polyrizon also reports on the advancement of its intranasal naloxone hydrogel within the Trap & Target™ platform. News items detail mucoadhesion and permeation studies comparing the formulation to a marketed intranasal naloxone product, as well as broader commentary on the potential role of enhanced mucosal residence time in emergency opioid overdose reversal.
In addition to R&D and regulatory milestones, Polyrizon’s news flow includes strategic and corporate developments. The company has disclosed plans to explore revenue-generating investment opportunities in sectors such as defense, aviation, artificial intelligence, and real assets, alongside continued focus on its core medical pipeline. Investors and observers can use this news stream to monitor scientific progress, FDA-related steps such as pre-submission meetings and Pre-Request for Designation filings, capital structure actions like reverse share splits, and broader strategic decisions that may influence the PLRZ stock story over time.
Polyrizon (Nasdaq: PLRZ) announced publication of U.S. patent application US 2024/0358741 A1 for its Trap & Target™ mucoadhesive polymer platform for nasal drug delivery.
The biocompatible hydrogels aim to enhance mucosal retention, drug absorption, and sprayable film-forming delivery across nasal and other mucosal routes.
Polyrizon (Nasdaq: PLRZ) signed agreements with a leading European university medical center and a specialized CRO to run a human performance and characterization study of its NASARIX™ (PL-14) Allergy Blocker.
The single-site study in healthy participants will measure nasal residence time, informing barrier duration and supporting the company’s V&V program and planned FDA submissions, under MDR and GCP standards.
Polyrizon (Nasdaq: PLRZ) announced that the European Patent Office has completed technical preparations to publish its European patent application EP 4751737, titled “Mucoadhesive Polymers for Nasal Drug Delivery.”
The application covers Polyrizon’s Trap & Target™ mucoadhesive nasal polymer platform, aimed at improving nasal formulation retention, drug absorption and delivery efficiency, and strengthening the company’s intellectual property position in European markets, subject to successful examination and potential grant.
Polyrizon (Nasdaq: PLRZ) signed agreements with two additional U.S. clinical sites, bringing the total to three major centers contracted for its upcoming NASARIX™ (PL-14) multi-center trial in seasonal allergic rhinitis.
The study will test safety, tolerability, and efficacy of NASARIX™ Allergy Blocker, an intranasal hydrogel designed to form a protective barrier against airborne allergens, at up to five U.S. sites under GCP standards.
Polyrizon (Nasdaq: PLRZ) signed its first U.S. Clinical Trial Agreement for the NASARIX™ (PL-14) Allergy Blocker, advancing toward first-in-human trials.
The Texas site will join a planned multi-center study in seasonal allergic rhinitis, comparing NASARIX to saline spray under GCP and regulatory standards.
Polyrizon (Nasdaq: PLRZ) is developing Capture&Contain™, an intranasal hydrogel platform aiming to provide a fast, non-specific biophysical barrier at the nasal mucosa against respiratory viruses. In-vitro studies suggest reduced viral-host interaction for influenza and coronaviruses. Lead candidate PL-16 remains pre-clinical, and this is a paid promotional communication.
Polyrizon (Nasdaq: PLRZ) submitted amended U.S. patent claims expanding protection for its intranasal hydrogel drug delivery platform to cover mucoadhesive compositions, drug delivery systems, and methods of use. The claims reference sulfated polysaccharide polymers and additional polymeric components that form a uniform film on mucosal surfaces.
The platform is described as enabling prolonged residence time, improved bioavailability, controlled film formation, and versatility across drug types, supporting both local and systemic intranasal administration.
Polyrizon (Nasdaq: PLRZ) filed a divisional European patent application on April 27, 2026, for its Trap & Target (T&T) intranasal drug delivery platform. The filing targets protection for prolonged nasal residence, improved bioavailability, controlled release, drip prevention, biodegradable polymers, and broad drug compatibility.
The application complements a recent U.S. patent filing covering both T&T and Capture & Contain (C&C) platform technologies.
Polyrizon (NASDAQ: PLRZ) closed a registered direct offering and concurrent private placement on April 8, 2026, raising approximately $3.5 million in aggregate gross proceeds.
The transactions sold 388,888 Units or Pre-Funded Units at $9.00 per Unit (or $8.99999 per Pre-Funded Unit), included Pre-Funded Warrants and Common Warrants exercisable at $9.00, and result in 2,083,939 Ordinary Shares outstanding assuming all pre-funded warrants are exercised.
Polyrizon (NASDAQ: PLRZ) announced a registered direct offering and concurrent private placement expected to raise approximately $3.5 million. The transactions include 388,888 Units or Pre-Funded Units at $9.00 each and warrants exercisable at $9.00 per share.
Closing is expected on or about April 8, 2026, subject to customary conditions; Aegis Capital is acting as exclusive placement agent.